ArticlePharmacoEconomics - open2026

Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain.

Elena Villamañan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.